BioNxt Solutions Announces Development of Sublingual Thin-Film for Semaglutide
BioNxt Solutions announces the development of BNT24005, a sublingual thin-film oral dissolvable film for Semaglutide, aiming to address limitations of existing injection methods. The innovation targets the growing diabetes and obesity treatment market, where Semaglutide (marketed as Ozempic® and Wegovy®) generated over $14 billion in revenue globally in 2023. The new delivery system offers key benefits including needle-free convenience, rapid absorption, enhanced bioavailability, and improved patient compliance. The product is currently under development and subject to regulatory review and approval.
BioNxt Solutions annuncia lo sviluppo di BNT24005, un film sottile dissolvibile orale sublinguale per Semaglutide, con l'obiettivo di affrontare le limitazioni dei metodi di iniezione esistenti. L'innovazione si rivolge al crescente mercato dei trattamenti per il diabete e l'obesità, dove Semaglutide (commercializzato come Ozempic® e Wegovy®) ha generato oltre 14 miliardi di dollari di fatturato a livello globale nel 2023. Il nuovo sistema di somministrazione offre vantaggi chiave tra cui la comodità senza aghi, l'assorbimento rapido, la maggiore biodisponibilità e una migliore aderenza da parte dei pazienti. Il prodotto è attualmente in fase di sviluppo e soggetto a revisione e approvazione normativa.
BioNxt Solutions anuncia el desarrollo de BNT24005, una película disoluble sublingual para Semaglutide, con el objetivo de abordar las limitaciones de los métodos de inyección existentes. La innovación está destinada al creciente mercado de tratamientos para la diabetes y la obesidad, donde Semaglutide (comercializado como Ozempic® y Wegovy®) generó más de 14 mil millones de dólares en ingresos a nivel mundial en 2023. El nuevo sistema de entrega ofrece beneficios clave, incluyendo la comodidad sin agujas, la rápida absorción, la mayor biodisponibilidad y una mejor adherencia del paciente. El producto se encuentra actualmente en desarrollo y sujeto a revisión y aprobación regulatoria.
BioNxt Solutions는 기존 주사 방법의 한계를 해결하기 위해 세마글루타이드를 위한 설하용 얇은 필름 구강용 용해 필름 BNT24005의 개발을 발표했습니다. 이 혁신은 세마글루타이드(오젬픽® 및 웨고비®로 판매)로 2023년 전 세계에서 140억 달러 이상의 수익을 창출한 당뇨병 및 비만 치료 시장의 성장에 주목하고 있습니다. 새로운 전달 시스템은 바늘 없는 편리함, 빠른 흡수, 강화된 생체이용률 및 개선된 환자 순응도와 같은 주요 이점을 제공합니다. 이 제품은 현재 개발 중이며 규제 검토 및 승인을 받기 위한 절차에 있습니다.
BioNxt Solutions annonce le développement de BNT24005, un film oral dissolvable sublingual pour Sémaglutide, visant à surmonter les limites des méthodes d'injection existantes. L'innovation cible le marché croissant des traitements pour le diabète et l'obésité, où Sémaglutide (commercialisé sous les noms de Ozempic® et Wegovy®) a généré plus de 14 milliards de dollars de revenus mondiaux en 2023. Le nouveau système de délivrance offre des avantages clés, notamment la commodité sans aiguille, une absorption rapide, une meilleure biodisponibilité et une conformité améliorée des patients. Le produit est actuellement en cours de développement et soumis à un examen et à une approbation réglementaire.
BioNxt Solutions kündigt die Entwicklung von BNT24005 an, einem sublingualen, dünnen, oral löslichen Film für Semaglutid, das die Grenzen bestehender Injektionsmethoden adressieren soll. Die Innovation zielt auf den wachsenden Markt für Diabetes- und Adipositasbehandlungen ab, in dem Semaglutid (vermarktet als Ozempic® und Wegovy®) 2023 weltweit über 14 Milliarden Dollar Umsatz erzielte. Das neue Abgabesystem bietet wesentliche Vorteile, darunter die Nadel-Freiheit, schnelle Absorption, verbesserte Bioverfügbarkeit und bessere Patientenadhärenz. Das Produkt befindet sich derzeit in der Entwicklungsphase und unterliegt der regulatorischen Überprüfung und Genehmigung.
- Product targets $14B+ global Semaglutide market (2023)
- Innovative delivery system addresses key limitations of injectable formats
- Technology potentially improves patient compliance and accessibility
- Product targets large market with 537M+ adults with diabetes globally
- Product still under development, pending regulatory approval
- Must navigate existing Novo Nordisk patent restrictions
- No proven efficacy or bioavailability data presented
VANCOUVER, BC / ACCESSWIRE / December 2, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery systems, announces the development of a sublingual thin-film oral dissolvable film (ODF) for Semaglutide, internally identified as BNT24005. This innovative product is intended to address limitations of existing administration methods for a therapeutic developed by Novo Nordisk, with the aim of improving patient accessibility and convenience. This product is currently under development and remains subject to regulatory review and approval.
Semaglutide: A Proven Therapeutic Leader
Semaglutide, developed by Novo Nordisk and marketed under brand names such as Ozempic® and Wegovy®, has revolutionized treatment for Type 2 diabetes and obesity. By mimicking glucagon-like peptide-1 (GLP-1), it enhances insulin secretion, reduces appetite, and slows gastric emptying, offering powerful tools for glycemic control and weight management.
In 2023, Semaglutide generated over
The BioNxt Advantage
Despite Semaglutide's success, its injectable format presents barriers, including needle anxiety and challenges with long-term adherence. BioNxt's sublingual thin-film technology, BNT24005, offers a novel delivery system that aims to reduce these hurdles, improving the overall patient experience.
Key benefits of the sublingual thin-film include:
Needle-Free Convenience: A painless and discreet alternative to injections.
Rapid Absorption: Direct sublingual delivery for faster therapeutic action.
Enhanced Bioavailability: Reduced enzymatic degradation compared to traditional oral routes.
Improved Patient Compliance: A portable, user-friendly format designed to encourage long-term adherence.
This next-generation delivery method has the potential to address unmet needs in diabetes and obesity care, aligning with global trends favoring patient-centric solutions.
Significant Market Opportunity
The global burden of diabetes and obesity underscores the growing need for innovative treatments. According to the International Diabetes Federation, over 537 million adults worldwide are living with diabetes, and the prevalence of obesity continues to rise.
Semaglutide's existing market success highlights the potential for innovative delivery systems. BioNxt aims to address patient challenges while adhering to stringent regulatory and intellectual property standards.
Strategic Development and Patent Positioning
BioNxt's thin-film innovation focuses on enhancing drug delivery methods without infringing on existing molecule patents. The product leverages a strategy centered on patentable administration improvements, respecting the intellectual property of Novo Nordisk.
BioNxt's Broader Pipeline of Innovations
The Semaglutide thin-film, BNT24005, is part of BioNxt's broader portfolio of advanced drug delivery technologies, targeting therapeutic areas such as neurodegenerative diseases, metabolic disorders, and other high-need markets. BioNxt's platforms include sublingual thin-films, transdermal patches, and enteric-coated oral tablets, all designed to enhance patient outcomes and healthcare accessibility.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablet)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity.
With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.
BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.
Investor Relations & Media Contact
Hugh Rogers, Co-Founder, CEO and Director
Email: investor.relations@bionxt.com
Phone: +1 780-818-6422
Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt-solutions
Instagram: https://www.instagram.com/bionxt
Cautionary Statement Regarding "Forward-Looking" Information
This press release contains forward-looking statements regarding the development, potential benefits, and commercialization of BioNxt's sublingual thin-film product for Semaglutide. These statements are based on current expectations and projections about future events but involve risks and uncertainties outside of the Company's control. Risks include challenges in obtaining regulatory approvals, potential intellectual property disputes or claims from third parties, and uncertainties associated with product development, manufacturing, and clinical validation. Additional risks include the potential for limited market acceptance of the sublingual thin-film technology and competitive pressures within the diabetes and obesity therapeutic sectors. Readers are cautioned that actual results may differ materially from those expressed in these forward-looking statements due to these and other factors. BioNxt Solutions Inc. undertakes no obligation to update forward-looking statements, except as required by applicable laws.
Trademarks: Trademarks Ozempic® and Wegovy® are registered trademarks of Novo Nordisk A/S and are referenced in this document solely for informational and comparative purposes to contextualize the market landscape. BioNxt Solutions Inc. is neither affiliated with nor endorsed by Novo Nordisk A/S.
SOURCE: BioNxt Solutions Inc.
View the original press release on accesswire.com
FAQ
What is BioNxt's new Semaglutide product BNT24005?
What are the advantages of BNXTF's sublingual Semaglutide film?
What is the current development status of BioNxt's Semaglutide film?
What market size is BioNxt (BNXTF) targeting with its Semaglutide film?
